In the last decade, site-directed administration and increased bioavailability have led to significant advances in cancer delivery technologies with nano-deliverable technologies (NDPs). Gold nanoparticles, liposomes, Dendrimers (Biodegradable Polyesters), and Mesoporous Silica are some of the most widely used nanoparticle systems in the field of cancer treatment. Retinoblastoma (RB) is a rapidly developing childhood eye cancer. Nanoparticle-based systems that have been mainly investigated for RB therapy have displayed improved drug delivery to the most restricted posterior segment of the eyes and have increased the intra-vitreal half-life of the chemotherapy agents highlighting its potential in the treatment of this form of cancer. It highlights the work that has been done to develop Nano-Dimensional Systems for RB treatment. This paper focuses on the current and emerging therapy options for diagnosing and treating the disease. It also describes how anticancer and imaging drugs can be actively directed to tumor cells with ligand-convulsant and smart nanoparticle applications. Finally, this paper discusses the opportunities and challenges in bringing this nano-carrier to clinical use for the treatment of RB. This paper may provide new perspectives for formulation researchers to study to support the development of safer and more effective medications for children with retinoblastoma.